Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Sun Pharmaceutical Industries LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:524715NSE Symbol: SUNPHARMAP/E(TTM):81.59
ISIN Demat:INE044A01036Div & Yield %:1.01EPS(TTM):19.48
Book Value(Rs):99.2482659Market Cap ( Cr.):381326.31Face Value(Rs):1
    Change Company 
Date Headline
23-Jan-26 Sun Pharma receives DCGI approval for generic version of semaglutide injection
21-Jan-26 Sun Pharmaceuticals Industries to convene board meeting
20-Jan-26 Sun Pharmaceutical Industries fixes record date for dividend
16-Jan-26 Volumes jump at Sun Pharmaceutical Industries Ltd counter
07-Jan-26 Sun Pharmaceutical Industries Ltd spurts 0.05%, gains for five straight sessions
30-Dec-25 Sun Pharmaceutical Industries Ltd eases for fifth straight session
18-Dec-25 USFDA classifies Sun Pharma's Baska facility inspection as Official Action Indicated
18-Dec-25 Sun Pharma declines after US FDA classifies Baska facility inspection as OAI
01-Dec-25 Sun Pharma launches innovative drug ILUMYA (Tildrakizumab) in India
17-Nov-25 Astrazeneca Pharma and Sun Pharma form second brand partnership
<< < 1 2 3 4   > >>